11:03 AM EST, 02/05/2025 (MT Newswires) -- Boston Scientific ( BSX ) reported stronger-than-expected fourth-quarter revenue on Wednesday amid a sharp gain in its cardiovascular segment, while guiding for a deceleration in top-line growth this year.

Revenue jumped to $4.56 billion for the three months ended Dec. 31 from $3.73 billion the year earlier and topped the $4.42 billion average analyst estimate on FactSet. Adjusted earnings per share advanced to $0.70 from $0.55 month to month.

Shares of the medical device maker were up 2.4% in Wednesday trade.

Cardiovascular sales jumped about 29% to $2.94 billion, while revenue rose 12% in MedSurg to $1.62 billion. Sales in its biggest geographic region, the US, advanced about 31%.

In a statement, Chief Executive Mike Mahoney called 2024 "one of the best years" in the company's history, which he said was "fueled by our innovative portfolio, the launch of our FARAPULSE Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions."

For 2025, Boston Scientific ( BSX ) expects sales to grow between 12.5% and 14.5% on a reported basis over 2024's sales of $16.75 billion, which was up nearly 18%. The FactSet consensus is for revenue of $18.81 billion in the ongoing year. Adjusted EPS is projected in the $2.80 to $2.87 range from 2024's $2.51.

"We expect to expand adjusted operating margin in 2025 by another 50 basis points to 75 basis points, balancing differentiated operating margin expansion while making targeted investments to fuel long-term top line growth," Chief Financial Officer Daniel Brennan told analysts on a conference call, according to a FactSet transcript. In 2024, adjusted operating margin improved 70 basis points to 27%, he said.

In the first quarter, sales are expected to increase between 17% and 19%, compared with $3.86 billion in the same quarter of 2024. Analysts are modeling for sales of $4.46 billion in the ongoing quarter. Boston Scientific ( BSX ) guided for adjusted EPS between $0.66 and $0.68, up from the $0.56 it reported in the same quarter last year.

Price: 105.53, Change: +1.99, Percent Change: +1.92